Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.

Meet Bioasis

BIO-Europe Spring

Bioasis Technologies Inc. (represented by John Proffitt of Shadow Lake Group) will be meeting with potential partners at BIO Europe Spring.

• March 20–22, 2023 | Basel, Switzerland
• March 28–30, 2023 | Digital

Please log in to register or schedule time to learn more about Bioasis Technologies Inc. and our xB³ platform.

Latest News

• Bioasis Provides Update on Business OperationsMar. 23, 2023

  NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...

• Bioasis Announces AGM Results and Provides Update on Financial PositionFeb. 3, 2023

  NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...

• Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcJan. 23, 2023

  NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...